Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00180401
Status:
TERMINATED
Last Update Posted:
2017-02-23
First Post:
2005-09-12
Brief Title:
MODULA-Study Modul 10 Benefit of CRT-Therapy in CRT-Patients With QRS-Complex of 120 - 150 Ms
Sponsor:
Boston Scientific Corporation
Organization:
Boston Scientific Corporation
Study Overview
Official Title:
MODULA-Study Modul 10 Benefit of CRT-therapy in CRT-Patients With QRS-complex of 120 - 150 ms
Status:
TERMINATED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
no longer interest from medical community
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the benefit of cardiac resynchronization therapy CRT-therapy in patients with a QRS-complex of 120-150 ms to patients with a QRS-complex of 150 ms
Detailed Description:
The objective of this study is to compare the benefit of CRT-therapy in patients with a QRS-complex of 120-150 ms to patients with a QRS-complex of 150 ms within 12 months A benefit is defined as change in quality of life and change in physical ability
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None